Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.078 AUD | +2.63% | +2.63% | -3.70% |
Mar. 20 | Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return | MT |
Feb. 16 | Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses | MT |
Sales 2022 | 182K 121K | Sales 2023 | 459K 306K | Capitalization | 15.03M 10.01M |
---|---|---|---|---|---|
Net income 2022 | -3M -2M | Net income 2023 | -7M -4.66M | EV / Sales 2022 | 43.1 x |
Net cash position 2022 | 29.34M 19.54M | Net cash position 2023 | 22.47M 14.96M | EV / Sales 2023 | -16.2 x |
P/E ratio 2022 |
-9.41
x | P/E ratio 2023 |
-1.94
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.21% |
1 day | +2.63% | ||
1 week | +2.63% | ||
Current month | -2.50% | ||
1 month | -9.30% | ||
3 months | -3.70% | ||
6 months | -67.50% | ||
Current year | -3.70% |
Managers | Title | Age | Since |
---|---|---|---|
Narelle Warren
DFI | Director of Finance/CFO | - | 19-02-28 |
Carol Parish
COO | Chief Operating Officer | - | - |
Thomas Duthy
BRD | Director/Board Member | - | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David McAuliffe
CHM | Chairman | 58 | 19-03-07 |
Narelle Warren
DFI | Director of Finance/CFO | - | 19-02-28 |
Thomas Duthy
BRD | Director/Board Member | - | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 0.078 | +2.63% | 210 |
24-06-04 | 0.076 | -5.00% | 68,200 |
24-06-03 | 0.08 | 0.00% | 6,321 |
24-05-31 | 0.08 | +5.26% | 164,532 |
Delayed Quote Australian S.E., June 04, 2024 at 11:15 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-3.70% | 4.02M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- IXC Stock